Investment
Features
FeesSafety
Academy
More
Pluang+
|
Home/Explore/US Market Price/Stocks/GILD
icon
Up to 4x
Us company
Asset icon - trade crypto, stocks, and gold on Pluang

Gilead Sciences, Inc. (GILD) Stock Price Today

TechnicalsFundamentalsFinancialsNewsCorp ActionAboutCompare
24H
1W
1M
3M
YTD
1Y
5Y

Aura AI Summary

Gilead Sciences (GILD) trades at $151.63, up 0.46% with a bullish technical signal and strong analyst support (65% buy ratings). Recent earnings show mixed results with Q2 2026 posting a loss but beating expectations, while revenue growth remains steady at $29.44B for 2025. The company maintains robust operating cash flow of $10.02B and recently expanded HIV prevention drug access through a PAHO partnership.
GILD presents a compelling growth story with strong HIV franchise performance and advancing oncology pipeline, though negative net income margin and elevated debt levels pose risks. The stock trades near consensus price target with institutional confidence, but investors should monitor pipeline execution and competitive pressures in biopharmaceutical markets.
Read full analysis

Key Stats

  • Market Cap
    $188.73B
  • Volume
    5,043,887
  • Sector
    Health
  • 52W High
    $155.80
  • 52W Low
    $110.56
  • Typical Hold Time
    110 Days
  • Enterprise Value
    $211.80B
  • Div Yield
    2.15%
  • Trading Activity
    36% Sell | 64% Buy
$151.89
52W Low: $110.56
02 Oct 2025
52W High: $155.8
11 Feb 2026

Track Gilead Sciences, Inc. (GILD) stock price today on Pluang, updated in real time with live charts and market data. Over the past 52 weeks, Gilead Sciences, Inc. has traded between a low of $110.56 and a high of $155.8, highlighting its annual price range. Buy and sell Gilead Sciences, Inc. shares on Pluang with fractional shares and real-time market data — safe and OJK-regulated.

About Gilead Sciences, Inc.

Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.

Most Recent News

Content is generated by Aura AI

uniQure shares drop 37% after mixed results in Huntington's gene therapy trial

uniQure's stock fell sharply by 37% following a four-year update on its AMT-130 gene therapy for Huntington's disease, which showed reduced effectiveness from 80% at three years to 44% at four years, failing to reach statistical significance. Despite...

Market News
4 hours ago
Andrew Wynn
Bearish
news icon
uniQure shares drop 37% after mixed results in Huntington's gene therapy trial

Gold and silver prices rise as softer US jobs and confidence data ease rate hike fears.

Gold and silver prices increased on Tuesday after weaker US labor market and consumer confidence data reduced expectations for aggressive interest rate hikes. Spot gold rose 1.42% to about $4,172 an ounce, while silver gained 1.23% to around $61.27. ...

Market News
4 hours ago
Kitco
Neutral
Gold and silver prices rise as softer US jobs and confidence data ease rate hike fears.

Sun Life appoints Darko Mihelic as new Head of Investor Relations starting October 2026

Sun Life Financial has named Darko Mihelic as its new Senior Vice-President and Head of Investor Relations, effective October 22, 2026. Mihelic joins from RBC Capital Markets, bringing extensive experience in equity research within Canada's financial...

Market News
4 hours ago
PRNewsWire
Neutral
Sun Life appoints Darko Mihelic as new Head of Investor Relations starting October 2026
Catch up fast with Aura AI
Get an AI-generated news summary for this asset in seconds.

People also bought

Frequently Asked Questions

US stocks trading hours: Monday - Friday (Except for US public holidays) Time: 21.30 - 04.00 WIB 20.30 - 03.00 WIB (Daylight Savings Time*) *The next Daylight Savings is scheduled to begin on March 13, 2022 and ends on November 6, 2022. You can place limit orders outside of the trading hours, but it can only be executed during trading hours. For illustration, a stock is currently trading at $10 per share, but you only want to pay $7 per share at most. Let’s say you set your limit price to $7 at 18.00. Your order will be executed when the market is open at 21.30 if the stock drops from $10 to $7 or lower. Similarly, if the stock price doesn’t drop to $7, your order won’t be executed.
Yes, you are eligible to receive dividend payment if and when the company pays them on one condition: minimum net dividend paid is at least $0.01. Net dividend is gross dividend subtracted by 15% withholding tax.
Yes, it is. US Stocks risk is managed by PT PG Berjangka which is licensed by Badan Pengawas Perdagangan Berjangka Komoditi (BAPPEBTI), and your investment is guaranteed by Jakarta Futures Exchange (JFX) and Indonesian Clearing House (KBI).
Pluang charges a fixed transaction fee of 0.30% for regular users and 0.20% for Pluang Plus members, including VAT to cover the exchange fees and operational costs.
US Stocks, ETFs, and Options are facilitated by PT PG Berjangka in its capacity as a Licensed Derivatives Broker supervised by the Financial Services Authority of Indonesia (OJK) for financial derivative products with underlying securities. All transactions are recorded on the Jakarta Futures Exchange (JFX) and the Indonesian Futures Clearing House (KBI). In addition, PT PG Berjangka is also a Licensed Futures Broker supervised by the Commodity Futures Trading Regulatory Agency (Bappebti). Read our product’s Terms and Conditions

All investments involve risks and the possibility of a loss in investment value. Past performance is not indicative of future results. Historical performance, expected returns, and probability projections are provided for informational and illustrative purposes only.

Key Stats

  • Market Cap
    $188.73B
  • Volume
    5,043,887
  • Sector
    Health
  • 52W High
    $155.80
  • 52W Low
    $110.56
  • Typical Hold Time
    110 Days
  • Enterprise Value
    $211.80B
  • Div Yield
    2.15%
  • Trading Activity
    36% Sell | 64% Buy
$151.89
52W Low: $110.56
02 Oct 2025
52W High: $155.8
11 Feb 2026

Track Gilead Sciences, Inc. (GILD) stock price today on Pluang, updated in real time with live charts and market data. Over the past 52 weeks, Gilead Sciences, Inc. has traded between a low of $110.56 and a high of $155.8, highlighting its annual price range. Buy and sell Gilead Sciences, Inc. shares on Pluang with fractional shares and real-time market data — safe and OJK-regulated.

Let’s invest in this asset by signing up or download!